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Comprehensive transcriptional profiling of glucose-
sensing neurons is challenging because of low
expression levels of glucokinase (Gck) and other
key proteins that transduce a glucose signal. To
overcome this, we generated and validated trans-
genic mice with a neuronal/endocrine-specific Gck
promoter driving cre expression and mated them
to mice with cre-dependent expression of an EGFP-
tagged ribosomal protein construct (EEF1A1LSL.
EGFPL10) that can be used to map and profile cells.
We found significantGck expression in hypothalamic
and limbic regions in cells that are activated follow-
ing administration of glucose or 2-deoxyglucose.
Transcriptional profiling fromGck-cre/EEF1A1LSL.
EGFPL10 mice enriched known and previously
unknown glucose-sensing populations including
neurons expressing growth hormone releasing
hormone (GHRH). Electrophysiological recordings
show that hypoglycemia activates GHRH neurons,
suggesting a mechanistic link between hypogly-
cemia and growth hormone release. These studies
provide a means for mapping glucose-sensitive
neurons and for generating transcriptional profiles
from other cell types expressing cre in a cell-specific
manner.
INTRODUCTION
The brain relies almost entirely on glucose as a source of energy
(Owen et al., 1967) and detects changes in plasma glucose
concentration. Glucose-sensing neurons in the CNS can elicit
potent effects on feeding behavior, thermoregulation, and
cardiovascular, lipid, and glucose metabolism (Frohman et al.,
1973; Porte et al., 1975) that help to maintain homeostasis and
also (partly) ensure that adequate nutrients are available to
the brain. Knowledge of the effect of the brain on peripheral
metabolism begins with the observation of Claude Bernard
that manipulation of the fourth ventricle altered hepatic glucose
production (Bernard et al., 1878). Since then, numerous studies
have identified distinct populations of neurons whose activity596 Cell Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inalters peripheral glucose metabolism (Berthoud et al., 1980;
Goto et al., 1980).
Glucose-sensing neurons use glucose as a metabolic sub-
strate and show changes in activity in response to changes
in extracellular glucose concentration (Fukuda et al., 1984;
Treherne and Ashford, 1991). Both inhibition and excitation
have been described in response to increases in extracellular
glucose concentration, suggesting that neuronal responses
may depend on more than one glucose-sensing mechanism
(Jordan et al., 2010).
In pancreatic b cells, glucose sensing relies on the low-affinity
Glut2 glucose transporter and glucokinase (Gck), a low-affinity
hexokinase that is the rate-limiting step in the phosphorylation
and utilization of glucose in these cells. The Km of Gck matches
plasma glucose concentration, and these proteins function as a
glucose sensor by correlating plasma glucose concentration
with cellular ATP concentration, which then inactivates ATP-sen-
sitive potassium channels (Rorsman, 1997). The glucose sensi-
tivity of the b cell correlates with Gck expression, and modifying
Gck activity alters the threshold for glucose sensing. In patients
with maturity onset diabetes of the young (MODY2), mutations
that increase the Km of Gck for glucose result in higher circu-
lating glucose levels, confirming a key role for Gck in glucose
sensing (Meglasson and Matschinsky, 1984).
A similar glucose-sensing mechanism is used by neurons, but
assessing the role of Gck in neuronal glucose sensing has
been limited by its low expression levels in the CNS. Initial
studies using transgenic mice with a Gck promoter driving
human growth hormone (GH) as a marker gene confirmed Gck
expression in the CNS but provided only low anatomical resolu-
tion (Jetton et al., 1994). Later in situ hybridization (ISH) studies in
rats identified several CNS regions expressing Gck, but again
expression levels were low (Lynch et al., 2000). While subse-
quent dual ISH for candidate neuropeptides showed overlap
between hypothalamic Gck and neurons expressing neuro-
peptide Y (NPY) mRNA (Lynch et al., 2000), the low expression
levels of Gck have limited a comprehensive identification of
glucose-sensing neurons.
Current techniques such as BAC-Trap analysis or FACS sort-
ing of fluorescently tagged neurons are not very effective at
generating molecular profiles from cells marked by genes
expressed at low levels. To map glucose-responsive neurons
in the CNS and identify molecular markers for subpopulations
of these neurons, we generated a Gck-cre mouse line and
crossed it to a new mouse line expressing a cre-dependentc.
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profiling using TRAP technology (Heiman et al., 2008). This
allowed us to both robustly map Gck expression and use
cre-dependent BAC TRAP to profile neurons expressing Gck.
These studies enabled us to confirm Gck expression in popu-
lations known to be glucose sensing and identified neural
populations expressing Gck that play a role in glucose sensing
in the CNS. This approach can now also be applied to studies
of other cell populations using transgenic mice that express
cre in specific cell types.
RESULTS
Generation and Validation of Glucokinase Cre Mice
Gck is expressed in numerous sites including the CNS,
pancreas, and neuroendocrine cells of the gastrointestinal tract
under the control of an upstream promoter directing expression
of a neuronal/endocrine-specific exon 1. Hepatic expression
is directed by a downstream promoter with an alternate liver-
specific exon 1 (Magnuson, 1992). To direct cre recombinase
expression to cells expressing neuronal Gck, we inserted the
cre gene downstream of the ATG of the neuronal/endocrine-
specific exon 1 (Figure 1, upper panel).
The Gck-cre transgenic mice were crossed to Rosa-LSL.YFP
reporter mice to activate expression of yellow fluorescent pro-
tein (YFP) in cre-expressing cells. Immunostaining for YFP in
the Gck-cre/Rosa-LSL.YFPmice showed YFP immunoreactivity
in several brain regions, with a similar pattern to that for Gck
expression demonstrated using ISH, including the hypothala-
mus, limbic system, and brain stem regions (see Figure S1
online). These regions have all been previously reported to be
sites of glucose sensing (Adachi et al., 1995; Dunn-Meynell
et al., 1997; Fukuda et al., 1984; Zhou et al., 2010), with the
only discrepancy being in cortex, where scattered neurons in
all layers expressed YFP without corresponding expression of
GckRNA (Figure S1; Table S1). Dual ISH forGck and immunohis-
tochemistry (IHC) for YFP demonstrated colocalization of Gck
mRNA and YFP in the hypothalamus, confirming that Gck-cre
mice expressed active cre recombinase specifically in Gck cells
(Figure 1, lower panels). YFP immunostaining was not seen in
liver, but there were immunopositive cells in pancreatic islets,
in keeping with previous reports of Gck expression in b and a
cells. There were also scattered cells with YFP immunoreactivity
through duodenum and ileum with a pattern suggestive of
neuroendocrine cells (Figure S1B); Gck has been reported to
be expressed in both K and L enteroendocrine cells. In summary,
glucokinase was widely expressed throughout the CNS with
high levels of expression in the hypothalamus and the limbic
system, and this pattern was replicated in Gck-cre mice.
Previous studies have reported Gck expression in glia, partic-
ularly tanycytes (Milla´n et al., 2010) in rats, and so we used dual
IHC for YFP in Gck-cre/ROSA-LSL.YFP and either the neuronal
marker, NeuN, or the glial marker, GFAP, found in both astro-
cytes and tanycytes. There was significant overlap of YFP and
NeuN staining; 69.9%± 6.2%of YFP-positive cells were colocal-
izedwith NeuN staining (Figure S1C). In addition, 30.8%± 11.8%
of YFP-positive cells were positive for GFAP staining. These
studies indicate that glucokinase expression was primarily
neuronal but that there was also expression in glia (Figure S1D).CellGlucokinase-Expressing Neurons Are Glucose
and Leptin Responsive
We next used IHC for the early intermediate gene product, c-fos,
to map neuronal activation in response to hyper- and hypoglyce-
mia and colocalized this immunostaining with that of YFP in
Gck-cre/Rosa-LSL.YFP mice.
As expected, intraperitoneal (i.p.) administration of glucose
in fasted mice induced c-fos immunoreactivity in several hypo-
thalamic regions, including the paraventricular nucleus (PVN),
dorsomedial hypothalamus (DMH), and lateral hypothalamus
(LH) (Dunn-Meynell et al., 1997). Cells expressing Gck (as indi-
cated by YFP expression) were activated by glucose adminis-
tration in several brain regions, with a significant increase in
the colocalization of YFP and c-fos in the DMH, LH, ventromedial
hypothalamus (VMH), and arcuate nucleus (ARC), but not the
PVN. These results suggested that Gck-expressing cells in the
DMH, LH, VMH, and ARC are components of the neural circuits
activated by hyperglycemia, while those in the PVN are not
(Figure 2).
We used 2-deoxyglucose (2-DG), a nonmetabolizable form
of glucose which enters the cell and inhibits glycolysis, to mimic
hypoglycemia (Landau and Lubs, 1958). c-fos immunoreactivity
following i.p. 2DG increased significantly in the PVN and insignif-
icantly in the VMH. Hypoglycemia induced a significant increase
in c-fos immunoreactivity in YFP immunopositive neurons in the
VMH, ARC, and LH (Figure 2). The c-fos response to hypoglyce-
mia suggested that Gck-expressing cells in these areas also
played a role in the neural pathways activated by low glucose.
Cells expressing Gckmay respond to other metabolic cues as
well as glucose. We confirmed this by treating Gck-cre/Rosa-
LSL.YFP mice with PBS or leptin and quantifying the number
of YFP-positive ARC cells that are also immunopositive for phos-
phorylated STAT3 (pSTAT3), a component of the intracellular
pathway activated by leptin binding to its receptor, Ob-Rb
(Ha˚kansson and Meister, 1998). Leptin treatment significantly
increased the number of YFP-positive cells that colocalized
with pSTAT3 immunostaining, indicating that a population of
ARC Gck cells respond to increases in circulating leptin (Fig-
ure S2). Consistent with prior reports, this suggests that ARC
Gck neurons may integrate both glucose and leptin signals
from the periphery.
Identifying Markers for Glucokinase-Expressing Neural
Populations
IHC of YFP in Gck-Cre/Rosa-LSL.YFP mice showed that Gck-
expressing cells are highly dispersed, suggesting that Gck
may mark a heterogeneous population. Identifying markers for
specific subpopulations of Gck-expressing cells would allow
functional assessment of their roles. To identify molecular
markers for Gck-expressing neurons, we profiled Gck neurons
using affinity purification of mRNA from EGFP-tagged poly-
somes (BAC-TRAP) (Doyle et al., 2008; Heiman et al., 2008). In
unpublished studies of Glucokinase–GFP mice, we concluded
from the low level of GFP immunoreactivity that Gck expression
could not drive sufficient expression of EGFP-tagged L10
ribosomal protein for ribosome purification. Instead, in this
case, we amplified expression by generating a mouse with cre-
dependent expression of EGFP-L10 from eukaryotic translation
elongation factor 1 alpha 1 (EEF1A1), a strong promoter that isMetabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inc. 597
Figure 1. Generation and Validation of Glucokinase Cre BAC Transgenic Mouse
(Upper panel) Generation of Gck-cre mice expressing cre under the control of the neuronal/endocrine Gck promoter. A nuclear localization signal, cre
recombinase, and poly(A) signal were inserted immediately downstream of the ATG in the first exon of the Gck BAC gene by homologous recombination. The
BAC includes 103 kb upstream and 110 kb downstream sequence. (Lower panel) Validation of GFP expression in the brain of Gck-cre/Rosa-LSL.YFP mice.
(A–C) Darkfield micrographs of endogenous Gck mRNA expression at three brain levels, using radioactive in situ hybridization (ISH).
(D–F) YFP-immunoreactivity (IR) in the ARC (D), LHA (E), and VMN (F) of brains from Gck-cre/Rosa-LSL.YFP mice.
(G–I) Double Gck-ISH/YFP-IR demonstrating colocalization of endogenous Gck mRNA expression (black grains) with that of the Gck-YFP reporter (brown
cytoplasmic stain) in neurons of the ARC (G), LH (H), and VM (I) fromGck-cre/Rosa-LSL.YFPmice. Abbreviations are as follows: MPOM, medial preoptic nucleus
(medial part); MnPO, median preoptic nucleus; LSV, lateral septal nucleus (ventral part); PVA, paraventricular thalamic nucleus (anterior part); PVN,
paraventricular nucleus of the hypothalamus; SPa, subparaventricular zone of the hypothalamus; SCh, suprachiasmatic nucleus; PV, paraventricular
thalamic nucleus; DMH, dorsomedial nucleus of the hypothalamus; LHA, laternal hypothalamic nucleus; VMN, ventromedial nucleus of the hypothalamus;
ARC, arcuate nucleus of the hypothalamus; and MePV, medial amygdaloidal nucleus (posteroventral part). Scale bars for (A)–(C), 1 mm; for (D)–(F), 100 mm; and
for (G)–(I), 25 mm. See also Figure S1.
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GHRH Neurons Are Activated by Hypoglycemiawidely expressed at high levels in the nervous system and in
most tissues (Klinakis et al., 2009).
Gene targeting in embryonic stem cells (ESCs) was used to
create mice with lox sites flanking a stop cassette placed up-
stream of an EGFPL10 cDNA. This cassette was targeted to
the EEF1A1 locus, and expression of EGFP-tagged ribosomal
protein gene can be activated by removing the floxed stop
cassette using cre recombinase (Figure 3A). To confirm this,
we generated mice with ubiquitous expression of EGFPL10
by crossing EEF1A1LSL.EGFPL10 mice with CMV-cre598 Cell Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inmice. IHC for GFP and the neuronal marker NeuN confirmed
widespread expression of EGFPL10 in the CNS (Figures 3B
and 3C). Next, we crossed EEF1A1LSL.EGFPL10 with Gck-
cre mice and analyzed GFP expression by IHC. The distribu-
tion of GFP in Gck-cre/EEF1A1LSL.EGFPL10 mice matched
the distribution of YFP in Gck-cre/Rosa-LSL.YFP mice, demon-
strating that cre-mediated activation of EEF1A1LSL.
EGFPL10 does not differ from that seen in the established
Rosa-LSL.YFP reporter line (Figure S3, upper panels; and
data not shown).c.
Figure 2. Gck-Expressing Cells Are Acti-
vated by Changes in Glucose
Gck-cre/Rosa-LSL.YFP mice were treated with
either i.p. PBS (control), 2-deoxyglucose (2-DG)
to mimic hypoglycemia, or glucose. Brains were
harvested, sectioned, and stained for YFP and
c-fos, a marker of neuronal activation (n = 3/
group).
(A) Dual immunohistochemistry for YFP and c-fos
in the ARC, DMH, LH, PVN, and VMH in control
(left panels), 2DG (center panels), and glucose-
treated (right panels) Gck-cre/Rosa-LSL.YFP
mice. Arrows indicate dual labeled cells. Scale bar,
50 mm.
(B) Quantification of c-fos immunoreactivity in
ARC, DMH, LH, VMN, and PVN regions with
control (PBS), 2DG, and glucose treatment. Data
are represented as mean ± SEM. Bars marked
with the same letter are significantly different
(p < 0.05).
(C) Quantification of number of YFP immunoreac-
tive cells that are also immunopositive for c-fos
indicating neuronal activation in the Gck-express-
ing cells in the ARC, DMH, LH, VMN, and PVN
regions. Data are represented as mean ± SEM.
Bars marked with the same letter are significantly
different (p < 0.05). See also Figure S2.
Cell Metabolism
GHRH Neurons Are Activated by HypoglycemiaHypothalamic tissue from adult Gck-cre/EEF1A1LSL.
EGFPL10 mice was used for extraction and affinity purification
of the EGFP-tagged polysomes. Messenger RNA was purified
from both total and EGFP-tagged polysomes followed by
in vitro transcription and labeling before hybridization to Illumina
MouseRef-8 v2.0 Expression BeadChip kit (Illumina, San Diego).
Gene expression data comparing expression levels in labeled
(i.e., polysomes from Gck-expressing cells) versus total hypo-
thalamic polysomes were collected from three independent
studies, each prepared from ten animals. Genes enriched in all
three studies were examined further. As expected, glucokinase
itself (fold enrichment = 4.9 ± 2.5, p < 0.05) and EGFP (fold
enrichment = 13.0 ± 1, p < 0.01) were significantly enriched in
the labeled polysomes (Figure S3, lower panels).
Genes for a number of hypothalamic neuropeptides were
also enriched inGck-expressing neurons (Figure S5). Expression
of orexin gene (Hcrt), encoding a neuropeptide found pre-
dominantly in a population of neurons that are inhibited
by glucose in the LH (Burdakov et al., 2006), was enriched inCell Metabolism 18, 596–607Gck neurons (fold enrichment = 2.8).
This was confirmed by qPCR of RNA pre-
pared by polysome precipitiation (fold
enrichment = 2.55 ± 1, p < 0.05) and by
dual IHC which showed that 36.5% ±
7% of neurons immunopositive for orexin
also express EGFP (Figure S4C). In
contrast, there was no enrichment in
the pro-melanin-concentrating hormone
gene (pMCH) and no colocalization of
Gck and melanin-concentrating hormone
(MCH) by IHC despite the fact that this
population is also known to be glucoseresponsive (Burdakov et al., 2005). ARC neurons including
those expressing pro-opiomelanocortin (POMC), NPY, and
agouti-related peptide (AGRP) genes have been shown to be
sensitive to glucose (Claret et al., 2011; Cowley et al., 1999;
Ma et al., 2008), and both POMC and AGRP mRNA were
enriched in RNA precipitated from polysomes from Gck-
expressing neurons. POMC expression in Gck neurons was
increased 3.6-fold in array data and by 9.5 ± 4.5-fold (p < 0.05)
using qPCR compared to total hypothalamic mRNA. Dual IHC
studies showed that 20% ± 6% of POMC-immunoreactive neu-
rons were positive for EGFP in Gck-cre/EEF1A1LSL.
EGFPL10 mice (Figure S4A). Similarly, AGRP expression was
also increased in Gck neurons by 2.9 ± 0.6-fold by qPCR (p <
0.05) and in Gck-cre/EEF1A1LSL.EGFPL10 mice 28% ± 8%
of AGRP-immunoreactive neurons colocalize with EGFP (Fig-
ure S4B). Consistent with prior electrophysiological studies of
these neurons, these data suggest that there is heterogeneity
among these populations of neurons and that only a subset of
POMC and NPY/Agrp immunoreactive neurons are glucose, October 1, 2013 ª2013 Elsevier Inc. 599
Figure 3. Generation and Validation of
EEF1A1–LSL.EGFPL10 Mice
(A) The highly expressed elongation factor 1 alpha
1 locus (EEF1A1) was used for knockin of a fusion
protein of EGFP and the large subunit ribosomal
protein L10 (top). cDNA for EGFPL10was inserted
into the multiple cloning site of a targeting vector
between an upstream 812 bp 50 homology arm,
splice acceptor site, floxed ‘‘stop’’ cassette with
neomycin selectable marker and a downstream
polyadenylation signal, and 3,606 bp 30 homology
arm (middle). Homologous recombination in ESCs
results in expression of a floxed ‘‘stop’’ cassette
and EGFPL10 with a polyadenylation site in the
EEF1A1 locus. Following cre-mediated recombi-
nation, the ‘‘stop’’ cassette is removed resulting in
expression of EGFPL10.
(B) Validation of EEF1A1LSL.EGFPL10mice was
performed by crossing to a CMV-cre mouse line
and dual IHC for GFP (left) and the neuronal
marker NeuN (center). Extensive colocalization of
GFP and NeuN was seen throughout the hypo-
thalamus (right).
(C) Dual IHC for GFP (left) and NeuN (center) in
CMV-cre/EEF1A1LSL.EGFPL10 mice shows
extensive colocalization throughout the hippo-
campus. Scale bar, 100 mm. See also Figure S3.
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the precipitated RNAs is available through GEO series accession
number GSE49868 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE49868).
Thus, despite the low level of Gck expression, using cre-
dependent activation of EGFP-L10 we have been able to
immunoprecipitate tagged polysomes to identify genes enriched
in Gck neurons. These studies identified neuropeptide
markers for several subpopulations of glucose-sensitive neu-
rons, enabling further characterization of their role in glucose ho-
meostasis. These data validated that the EEF1A1LSL.EGFPL1
0 mouse line can be used to profile neurons, or other cell types,
after crosses to cre-expressing mouse lines.
GHRH Neurons Are Glucose Responsive
Among the markers for neurons not previously known to be
glucose sensing, growth-hormone-releasing hormone (GHRH)
mRNA was significantly increased in Gck-expressing neurons
both by array (3.9-fold) and by qPCR (8.6- ± 2.5-fold, p < 0.05)
compared to total hypothalamic mRNA (Figure 4). Colocalization
studies were performed by crossingGck-cremice to the reporter
strain, Rosa-LSL.dtomato (Rosa-LSL.dTm), and then crossing600 Cell Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inc.the resulting Gck-cre/Rosa-LSL.dTm
offspring to GHRH-GFP mice. A signifi-
cant number of GHRHGFP-immunoreac-
tive neurons were found to be positive
for dTm (69% ± 7%), indicating coex-
pression of Gck in a majority of GHRH
neurons. Although GH plays a role in the
counterregulatory response to hypogly-
cemia, the full complement of mecha-
nisms by which hypoglycemia stimulatesGH release is not known (Bansal et al., 1981; Cordido et al., 1990;
Jaffe et al., 1996; Masuda et al., 1990). The finding that GHRH
neurons are highly colocalized with Gck suggested these cells
may be glucose sensing.
To investigate whether GHRH neurons are glucose sensing,
we performed whole-cell patch-clamp recordings from GHRH
neurons in hypothalamic mouse brain slices. GHRH neurons
fired at low frequency at various glucose concentrations. Mean
firing rate was 0.83 ± 0.17 Hz in 10mMglucose; at 4mMglucose
it was 1.0 ± 0.19 Hz, and at 0.2 mM glucose it was 1.43 ± 0.28 Hz
(n = 1220 cells). Recordingsweremade during the replacement
of a 10 mM glucose concentration with either 4 or 0.2 mM
glucose. Of the 20 cells recorded, only two neurons decreased
their firing rate in response to decreasing extracellular glucose,
while 18 showed an increase in firing rate. A reduction of external
glucose from 10 to 4 mM increased mean firing rate from 0.56 ±
0.13 Hz to 1.20 ± 0.21 Hz (p < 0.05). Similarly, reducing glucose
concentration from 10 to 0.2 mM significantly increased mean
firing rate from 0.79 ± 0.43 Hz to 1.75 ± 0.22 Hz (p < 0.05). To
exclude the possibility that this change in firing rate was a result
of time, recordings were continued upon restoration to 10 mM
glucose, and experiments were also performed starting at low
Figure 4. GHRH Neurons Express Glucokinase
(A) Transcriptional profiling from hypothalamic Gck-cre/EEF1A1LSL.EGFPL10-expressing neurons showed significant enrichment for GHRH mRNA when
compared to total mRNA (n = 4 immunoprecipitations, each with ten hypothalami pooled). Data are represented as mean ± SEM.
(B) Immunohistochemistry in GHRH-GFP/Gck-cre/ROSA-LSL.dTm mice. GHRH GFP mice expressing GFP under the control of the GHRH promoter were
crossed to Gck-cre/ROSA-LSL.dTm mice expressing dTm in Gck-expressing neurons. Immunohistochemistry for EGFP showed significant colocalization of
GFP in GHRH neurons and dTm in Gck neurons, which are present as yellow neurons in themerged images. Arrows indicate dual labeled cells. Scale bar, 100 mm
for all panels except for right panel, which is 25 mm.
(C) Quantification of GHRH GFP immunoreactive cells that colocalize with Gck-cre/ROSA-LSL.dTm cells (n = 3). Data are respresented as mean ± SEM. GHRH
neurons are highly colocalized with Gck-expressing cells as marked by the expression of dTm. See also Figure S4.
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centration (10 mM). Accordingly, changes in firing rate were
associated with a change in membrane potential such that
decreasing external glucose from 10 to 4 mM resulted in a sig-
nificant decrease in membrane potential of 7.46 ± 1.42 mV (p <
0.05) and from 10 to 0.2 mM also produced a significant
decrease in membrane potential of 12.42 ± 1.57 mV (p < 0.05)
(Figure 5F). These results indicate that GHRH neurons in the
ARC change their activity in response to changes in glucose
concentration and that low glucose leads to depolarization in
the majority of ARC GHRH neurons, increasing their firing rate.
These data show that GHRH neurons sense hypoglycemia.CellDISCUSSION
In these studies, we mapped sites of glucose sensing in the
CNS by generating a transgenic mouse that expresses cre under
the control of the neuronal/endocrine Gck promoter. The low
expression levels of Gck have limited the utility of previous
reporter strains such as those using the Gck promoter to drive
GH expression (Jetton et al., 1994). However, by expressing
cre downstream of the Gck promoter, we were able to amplify
the otherwise low expression levels.
The Gck-cre mouse line was validated by mating to a cre-
dependent YFP reporter strain, ROSA-LSL.YFP, resulting inMetabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inc. 601
Figure 5. Activity of GHRH Neurons Is Decreased in Response to Increases in Extracellular Glucose Concentration
(A) Representative trace of a current-clamp recording from aGFP-labeledGHRH neuron. After 2min, external [glucose] is decreased from 10 to 4mM, resulting in
an increase in firing rate. After 5 min, [glucose] is restored to 10 mM (scale bar, 20 mV, 1 min).
(B) Increasing the [glucose] from 0.2 to 10mM results in a reversible decrease in firing rate. Example trace of a current-clamp recording from aGFP-labeledGHRH
neuron. After 2 min, external [glucose] is increased from 0.2 to 10 mM, resulting in a decrease in action potentials. After 5 min, [glucose] is restored to 0.2 mM.
(C) Selected 10 s sections of a current-clamp recording from the same neuron in different [glucose]. In 10mMglucose, firing rate is low. This is increased in 0.2mM
glucose and returns to baseline in 10 mM glucose.
(D) Pooled raw values showing that GHRH neurons respond to an increase in [glucose] with a significant decrease in firing rate. Decreasing the [glucose] from
10 to 4 mM significantly increased the firing rate from 0.56 ± 0.13 to 1.20 ± 0.21Hz (n = 9, p < 0.05). Similarly, deceasing the [glucose] from 10 to 0.2 mM resulted
in an increase in mean firing rate from 0.79 ± 0.43 to 1.75 ± 0.22 Hz (n = 9, p < 0.05). Data are represented as mean ± SEM.
(E) Mean changes in membrane potential with changes in [glucose]. Changing from 10 to 4 mM resulted in a mean decrease of membrane potential of 7.46 ±
1.42 mV (n = 9, p < 0.05). Changing from 10 to 0.2 mM resulted in a decrease in membrane potential of 12.42 ± 1.57mV (n = 9, p < 0.05). Data are represented
as mean ± SEM.
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GHRH Neurons Are Activated by HypoglycemiaYFP expression in Gck-cre-expressing neurons. Dual ISH/IHC
validated the colocalization of cre-induced YFP with wild-type
Gck expression and enabled us to use YFP expression in the
Gck-cre/Rosa-LSL.YFP mice as a marker for Gck-expressing
neurons. YFP expression in Gck-cre/Rosa-LSL.YFP mice was
found extensively throughout the hypothalamus and limbic
system and matches that of known glucose-sensing popula-
tions (Dunn-Meynell et al., 1997; Fukuda et al., 1984; Silva and602 Cell Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier InBoulant, 1984). The expression pattern is similar to that detailed
in the rat brain by ISH (Lynch et al., 2000), though additional
sites of expression in mice include the anterior hypothalamic
area, and median and medial preoptic nuclei. However, charac-
terization of endogenous Gck expression by ISH is hampered
by low expression levels, and we may not have detected all
Gck expression despite amplification using radiolabeled in situ
probes.c.
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GHRH Neurons Are Activated by HypoglycemiaUsing YFP immunoreactivity as a marker of Gck expression in
Gck-cre/Rosa-LSL.YFPmice, we were further able to determine
if changes in peripheral glucose activated Gck-expressing pop-
ulations and to map their activation. We found that Gck ex-
pression, as marked by YFP immunoreactivity, colocalized with
neural populations activated by increased glucose and with
those activated by hypoglycemia. Increased glucose following
i.p. administration induced significant c-fos immunoreactivity
in the DMH, LH, and PVN, in keeping with previous studies
(Dunn-Meynell et al., 1997). Hyperglycemia induced a significant
increase in activated Gck neurons in the ARC, DMH, VMH, and
LH, but not in the PVN, suggesting that Gck neurons in these
regions, but not the PVN, form part of the glucose-activated
pathways. These results support a role for Gck in the neuronal
response to increased glucose. Earlier work using dual ISH in
rats colocalized Gck mRNA with ARC POMC expressing neu-
rons (Dunn-Meynell et al., 2002), a subset of which are activated
by glucose (Claret et al., 2011). In addition, Gck inhibitors
and siRNA against Gck blocked the glucose responsiveness of
dispersed glucose-excited neurons from the ARC/VMN region
(Kang et al., 2004, 2006). However, a role for Gck in glucose-
activated neurons in the DMH and LH has not previously been
described.
Hypoglycemia activated hypothalamic neurons as expected,
primarily in the PVN and but also in the VMH (Briski, 1998), and
also activated Gck-expressing neural populations. Significant
colocalization of YFP and hypoglycemia-induced c-fos immu-
noreactivity were found in the ARC, VMN, and LH. Previous
studies have noted that a significant subpopulation of ARC/
VMN and LH neurons are glucose inhibited. In rats, Gck inhi-
bitors alter c-fos immunoreactivity in ARC AGRP neurons and
LH orexin neurons (Zhou et al., 2011), and siRNA toGck blocked
the activity of glucose-inhibited neurons in the VMH (ARC and
VMN) (Kang et al., 2006). Our findings also suggest theGck is co-
localized with glucose-inhibited populations in the ARC and LH.
We also wanted to determine if Gck-expressing neurons were
capable of responding to metabolic signals other than glucose
and found that ARC neurons expressing Gck are activated
by leptin. Gck-expressing neurons may therefore act both as
glucose sensors and as general metabolic sensors to integrate
acute changes in blood glucose with signals of longer-term
energy status provided by leptin. In keeping with this, previous
studies have noted that subpopulations of POMC neurons
respond to changes in glucose, leptin, or insulin (Claret et al.,
2011; Ma et al., 2008). This finding suggests the possibility that
changes in the circulating levels of leptin could alter the physio-
logical responses to hyper- and hypoglycemia.
The widely dispersed expression of Gck and its colocalization
with neural pathways activated by both hyper- and hypoglyce-
mia suggest that several neural and glial populations sense
changes in extracellular glucose concentrations. To further
dissect the role of Gck neurons in the physiological responses
to altered glucose, we need to havemarkers for component sub-
populations, allowing analysis of their functional role(s) in medi-
ating the responses to hyper- and hypoglycemia. To accomplish
this, we used a modification of BAC-TRAP translational profiling
by generating mice expressing cre-dependent EGFP-tagged
ribosomal protein L10 and crossing these to Gck-cre mice.
Crossing Gck-cre mice to EEF1A1LSL.EGFPL10 mice led toCellhigh levels of EGFP-tagged polysomes specifically within Gck-
expressing neurons and allowed enrichment of genes expressed
in Gck neurons. Consistent with prior data, this technique iden-
tified genes encoding neuropeptides that mark previously
identified glucose-sensing neural populations, i.e., Hcrt, AGRP,
and POMC, though the role(s) of Gck in these populations is
not fully understood (Burdakov et al., 2006; Cowley et al.,
1999; Parton et al., 2007).
In our studies, GHRH was one of the most highly enriched
transcripts in Gck neurons, and a majority of GHRH neurons
colocalize with Gck-expressing cells. In electrophysiological
studies, we demonstrated that GHRH neurons are depolarized
and activated by decreased glucose. Hypoglycemia has been
used as a clinical tool to assess the integrity of the GH response,
but the mechanism of action is unclear. Hypotheses have
included modulation in somatostatin inhibition (Masuda et al.,
1990), catecholaminergic stimulation (Blackard and Heidings-
felder, 1968), and opioid modulation (Thompson et al., 1985)
of GH release. Though GHRH release from hypothalamic ex-
plants is stimulated by hypoglycemia (Lewis et al., 1989), there
have been no previous studies examining whether GHRH
neurons are glucose responsive. Further studies are needed
to determine the role of Gck in the response of GHRH neurons
to hypoglycemia.
GHRH and GH form part of the physiological counterregu-
latory response to hypoglycemia. GHRH deficiency worsens
hypoglycemia and impairs recovery in rodents and humans
(Hussain et al., 2003; Tennese and Wevrick, 2011). Recent
work has also emphasized the importance of the GH axis in
the counterregulatory response to low glucose in fasting and
further identified a role for ghrelin. Mice lacking octanoylated
ghrelin have a blunted, though not absent, plasma GH response
to calorie restriction, resulting in profound hypoglycemia and
death (Goldstein et al., 2011). While ghrelin receptors are found
on ARC NPY neurons, ghrelin has also been reported to stimu-
late GHRH neurons directly (Osterstock et al., 2010). It is thus
possible that ghrelin, together with GHRH neuronal acitvation
by hypoglycemia, as shown in this report, activates GHRH
neurons during hypoglycemia.
Several studies have demonstrated that lateral hypothalamic
orexin neurons are inhibited by glucose (Gonza´lez et al., 2008;
Zhou et al., 2011). However, the evidence for a role for Gck is
contradictory. Dual ISH in rats has previously shown colocaliza-
tion of Hcrt and Gck in rats (Dunn-Meynell et al., 2002) and c-fos
immunoreactivity in orexin neurons following Gck inhibition
(Zhou et al., 2011). However, in ex vivo recordings from orexin
neurons, glucose inhibition was preserved in the presence of
Gck inhibitors (Gonza´lez et al., 2008), and 2-DG, which can be
phosphorylated by Gck but cannot regulate ATP/ADP ratios,
also inhibited orexin neurons. These results suggest that Gck
is not key to glucose sensing in these neurons. Further studies
will be necessary to establish the effects of altered Gck activity
on glucose sensing in orexin neurons in vitro and in vivo.
In the ARC, both AGRP and POMC are enriched in Gck-
expressing neurons. In rats, Gck expression has been reported
in ARC POMC neurons and in ARC NPY neurons that also
express AGRP (Dunn-Meynell et al., 2002). A subpopulation of
AGRP neurons (less than one-third) have been shown to be
glucose excited in ex vivo slices, but at least in some studies,Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inc. 603
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phy et al., 2009). Electrophysiology in ex vivo rat hypothalami
showed that glucose inhibition of medial ARC neurons (where
NPY/Agrp neurons predominate) is modified by the Gck inhi-
bitor, alloxan (Wang et al., 2004). Also, the Gck inhibitor, glucos-
amine, induces c-fos immunoreactivity in ARC AGRP neurons
(Zhou et al., 2011). Further studies in glucose-inhibited neurons,
for example by manipulating Gck, potassium, or chloride
channel gene expression, are required to elucidate the role(s)
of Gck and the downstream mechanisms mediating neural
inhibition by glucose.
Finally, the approach and resources that we developed pro-
vide a means for further studying hypothalamic glucose-sensing
neurons, as well as glucose sensing in other regions. Transcrip-
tional profiling from EEF1A1LSL.EGFPL10 mice could thus be
used to identify neuropeptide markers for glucose-sensing
populations in these extrahypothalamic regions. The limbic
system, including the amygdala, BST, and thalamic nuclei,
contain many neurons expressing Gck. Identifying markers for
these populations would then allow us to address the role(s)
of these glucose-sensing neurons in autonomic and other
responses to changing glucose.
While polysome precipitation from Gck-expressing neurons
identified several known glucose-responsive populations, we
may not have identified all glucose-sensing populations. In
particular, we did not enrich for pMCH or find any colocalization
between YFP and MCH immunoreactivity in Gck-cre/Rosa-
LSL.YFP mice using dual IHC. A number of glucose-sensing
mechanisms have been proposed, including sodium-glucose
co-transporters, glucose-lactate shuttle, and glucose receptors
(Jordan et al., 2010), and it is possible that one of these mecha-
nisms is operative in MCH neurons. It is also possible that Gck
may be expressed under the control of a different promoter,
either the hepatic Gck promoter or an as-yet-unknown one.
Transcriptional profiling of MCH neurons may help identify
additional glucose-sensing mechanism in these cells and is
now underway. Identification of additional glucose sensors
might also be possible by immunoprecipitation of neurons ex-
pressing Kir6.2, a component of the KATP channel which is
thought to be a final step in the multistep pathway from glucose
sensing to neuronal depolarization. Immunoprecipitation of
neurons from EEF1A1LSL.EGFPL10 mice crossed to Kir6.2-
cre mice may provide valuable additional information about
glucose sensing mechanisms (Parton et al., 2007). In addition,
while we achieved 4.9-fold enrichment of Gck mRNA, which is
in keeping with prior studies (Doyle et al., 2008; Sanz et al.,
2009), this enrichment may not be sufficient to detect markers
from less highly colocalized populations.
The EEF1A1LSL.EGFPL10 mouse line will be beneficial in
transcriptional profiling from a broad range of cre-expressing
cell populations both in the CNS and in the periphery. We have
validated the EEF1A1LSL.EGFPL10 mouse line by colocaliza-
tion of GFP in other cre-expressing mice with markers that are
abundantly expressed, including DAT-cre and pMCH-cre mice
and confirmed eutopic expression (our unpublished data). The
EEF1A1LSL.EGFPL10 mouse line is advantageous in that it
limits the need to generate additional mouse lines for BAC-
TRAP. In addition, because it amplifies the signal of the promoter
driving cre expression, the approach is suited to transcriptional604 Cell Metabolism 18, 596–607, October 1, 2013 ª2013 Elsevier Inprofiling of neural populations marked by genes expressed
at low levels, a feature that was particularly important for Gck-
expressing neurons. Previous work by Sanz et al. (Sanz et al.,
2009) described a mouse line with cre-dependent expression
of an HA-tagged ribosomal protein, L22, and the ability to
immunoprecipitate known markers from cell populations with
high levels of cre expression such as DAT-cre. Ribosomal pro-
tein genes such as RPL22 are expressed at much lower levels
than the EEF1A1 locus used in our system (Allen Brain Atlas),
which might limit the utility of the cre-expendent tagged RPL22
in profiling target genes with low abundance. We showed that
our system has the ability to identify known and previously
unknown markers from neural populations with low levels of
cre expression that could not be identified with conventional
BAC-TRAP.
In summary, we generated mice with the neuronal/endocrine-
specific Gck promoter driving cre expression and showed that
Gck, a candidate neuronal glucose sensor, neurons are present
in hypothalamic nuclei and additional brain regions known to
respond to glucose. There is significant activation of Gck-
expressing neurons in distinct hypothalamic regions with hyper-
glycemia and also with hypoglycemia. These findings provide
additional evidence, albeit indirect, to support a role for Gck in
neuronal glucose sensing. We were able to generate a molecular
profile of Gck-expressing neurons by mated Gck-cre mice to
mice expressing a conditional EGFP-tagged ribosomal protein
construct suitable for BAC-Trap analysis. Translational profiling
of Gck-expressing neurons allowed us to identify markers for
subpopulations of neurons that coexpress Gck. These findings
include known glucose-responsive populations, such as those
immunoreactive for Agrp, POMC, and orexin, where the role of
Gck in the ability to sense glucose would benefit from further
study.Wealsoshowed thatGHRHneurons arehighly colocalized
with Gck, and electrophysiological studies demonstrate that
this population is glucose inhibited. These studies will now allow
us to use functional tools such as optogenetics (Boyden et al.,
2005), radiogenetics (Stanley et al., 2012), or pharmacological
manipulation (Nawaratne et al., 2008) to assess the contribution
of individual Gck-expressing subpopulations, and the role of
Gck within these populations, to the physiological regulation of
blood glucose. These studies also show the utility and validate
that the EEF1A1LSL.EGFPL10 mice can be used to profile
neurons, or other cell types, from cre-expressing mouse lines.
EXPERIMENTAL PROCEDURES
Animals
Male C57Bl6 and transgenic mice were used. Rosa-LSL.YFP mice and Rosa-
LSL.dTm mice were purchased from Jackson Laboratories. GHRH-GFPmice
were a kind gift of Dr. Iain Robinson (MRC National Institute for Medical
Research, London, UK). Animal care and experimental procedures were per-
formed with approval from the Animal Care and Use Committee of Rockefeller
University under established guidelines.
The Gck-cre transgenic mice were created using BAC transgenic technol-
ogy (Figure 1) (Yang et al., 1997), and EEF1A1LSL.EGFPL10 transgenic
mice were generated by standard knockin techniques (Figure 3) (Klinakis
et al., 2009).
Immunofluorescence and GFP Colocalization
Immunofluorescence and double labeling were performed as previously
described (Stanley et al., 2010). Briefly, anesthetized mice were transcardiallyc.
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GHRH Neurons Are Activated by Hypoglycemiaperfused with 4% paraformaldehyde (PFA). Brains were then sectioned by
vibratome. Sections were washed, blocked with 3% BSA and 2% goat serum
in 0.1% Triton-X in PBS for 1 hr, and then incubated with primary antibody
for 16 hr at 4C. Sections were rinsed, incubated with fluorophore-labeled sec-
ondary antibodies for 2 hr at RT, then mounted and covered. Transgenic mice
stained for Agrp were treated with colchicine to enhance cell body staining as
described in the Supplemental Information. Microscopy was performed with a
Zeiss Inverted LSM 780 laser scanning confocal microscope. Structures were
defined according to their morphology compared to the sections illustrated
in Paxinos and Franklin (2001). Nomenclature was based on Paxinos and
Franklin.
In Situ Hybridization Histochemistry and Immunohistochemistry
of Gck-cre/Rosa-LSL.YFP Mice
Anesthetized mice were perfused (as above) and then dehydrated in 20%
sucrose and sections cut on a freezing sliding microtome. A Gck riboprobe
specific to 809 nt segment of mouse Gck mRNA (Allen brain atlas Probe
RP_041208_02_A03) was generated to detect endogenously encoded Gck
and not that arising from the modified BAC. 35S-labeled cRNA probes (sense
and antisense) were used to detect endogenous Gck followed by IHC to YFP
as previously described (Stanley et al., 2010). Photomicrographs were pro-
duced using a Zeiss Axioskop 2 mot plus with an interface with a Pentium III
computer. Images were compiled with Adobe Photoshop (6.0) software.
Immunoprecipitation of Polysomes
Ten mice for each replicated sample were euthanized, and hypothalami were
dissected. Immunoprecipitations were performed with a mix of two anti-GFP
monoclonal antibodies (19C8, 19F7). RNA quantity and quality were measured
with a Nanodrop 1000 spectrophotometer (Wilmington, DE) and Agilent
Bioanalyzer (Santa Clara, CA), respectively. Ten nanograms of total RNA
was amplified and labeled using Nugen Ovation PicoSL WTA System
(San Carlos, CA) and hybridized to Illumina MouseRef-8 v2.0 Expression
BeadChip Kit (Illumina, San Diego, CA). Each immunoprecipitation was
performed in triplicate.
Microarray Normalization and Analysis
Samples were normalized by GCRMA, then filtered to remove probesets with
low signal. Immunoprecipitated (IPed) samples were compared to total sam-
ples from the same experiment, and a ratio of IPed to total samples was
used. Genes with fold changes greater than 1.5 in all three replicates were
considered significant. Analysis was performed using Genespring GX (Agilent,
Santa Clara, CA).
Quantitative Real-Time PCR
Complimentary DNAwas synthesized usingQIAGEN superscript RT kit (Venlo,
Netherlands). Real-time PCR was performed using the TaqMan system
(Applied Biosystems; Foster City, CA) according to the manufacturer’s
protocol.
Slice Preparation and Electrophysiology
Coronal hypothalamic slices (200 mm) were taken from male GHRH-GFPmice
(3–8 weeks old) as previously described (Sternson et al., 2005). Whole-cell
current-clamp recordings were made at room temperature from GFP-labeled
neurons in the ARC. Recordings were acquired with an Axopatch 200B
amplifier, filtered to 2 kHz, and digitized at 10 kHz (pClamp10 software,
Molecular Devices). Data were analyzed using IGOR Pro (Wavemetrics) and
NeuroMatic (http://www.neuromatic.thinkrandom.com/).
Statistics
All data were analyzed for statistical significance using the Student’s t test
unless otherwise stated. Results are shown as average ± SEM. p values are
as indicated.
SUPPLEMENTAL INFORMATION
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